Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14980018 | 0.83 | SIGMAR1 (0.55) | SIGMAR1L3MBTL3POLBHRH3EPHX2 | |
| SCHEMBL15137345 | 0.81 | SIGMAR1 (0.57) | SIGMAR1L3MBTL3POLBHRH3EPHX2 | |
| SCHEMBL13283790 | 0.80 | SIGMAR1 (0.53) | SIGMAR1L3MBTL3POLBHRH3EPHX2 | |
| SCHEMBL8009145 | 0.80 | SIGMAR1 (0.55) | SIGMAR1L3MBTL3POLBHRH3EPHX2 | |
| SCHEMBL4547889 | 0.80 | SIGMAR1 (0.59) | SIGMAR1L3MBTL3POLBHRH3L3MBTL1 | |
| SCHEMBL28069120 | 0.79 | KDM4E (0.59) | HRH3EPHX2L3MBTL1 | |
| SCHEMBL17660231 | 0.79 | SPHK1 (0.58) | HRH3L3MBTL1AVPR1B | |
| SCHEMBL3637477 | 0.79 | SIGMAR1 (0.51) | SIGMAR1L3MBTL3POLBHRH3EPHX2 | |
| SCHEMBL7901419 | 0.79 | SIGMAR1 (0.55) | SIGMAR1L3MBTL3POLBHRH3EPHX2 | |
| SCHEMBL24022514 | 0.77 | SIGMAR1 (0.60) | SIGMAR1L3MBTL3POLBHRH3MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9637492-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637492-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-20140377285-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2014-12-25 | — | — | US | disclosed |
| US-20140357651-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CALITHERA BIOSCIENCES, INC. | 2014-12-04 | — | — | US | disclosed |
| US-20140128599-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2014-05-08 | — | — | US | disclosed |
| US-8476431-B2 | Benzoxazole kinase inhibitors and methods of use | Itellikine LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8450480-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128599-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | BMX, MTOR, PDPK1 | SIGMAR1 2384/4885L3MBTL3 4326/4885SYK 271/4885 |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | MTOR, PDPK1, PIKFYVE | SIGMAR1 3041/4885L3MBTL3 2918/4885SYK 445/4885 |
| US-20140377285-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | SIGMAR1 3030/4885L3MBTL3 4273/4885SYK 1922/4885 |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | AURKC, MTOR, AURKA | SIGMAR1 4197/4885L3MBTL3 1269/4885SYK 2703/4885 |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | SIGMAR1 2384/4885L3MBTL3 4326/4885SYK 271/4885 |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | CDC25C, CCNC, CDC25B | SIGMAR1 4139/4885L3MBTL3 4005/4885SYK 4517/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | SIGMAR1 3030/4885L3MBTL3 4273/4885SYK 1922/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | SIGMAR1 2591/4885L3MBTL3 1115/4885SYK 451/4885 |
| US-20140357651-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CDC25C, CCNC, CDC25B | SIGMAR1 4139/4885L3MBTL3 4005/4885SYK 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.